Chemoprevention of Lung Cancer Is Proving Difficult and Frustrating, Requiring New Approaches
Open Access
- 21 June 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 92 (12) , 959-960
Abstract
The long-awaited results from EUROSCAN (i.e., the European Study on Chemoprevention With Vitamin A and N-Acetylcysteine), the randomized two-by-two factorial trial of vitamin A (retinyl palmitate) and N-acetylcysteine in patients with treated cancers of the lung or head and neck, show no benefit from either agent alone or from the combination. Among 2592 participants who received maximal tolerable doses for 2 years with a mean follow-up of 49 months, 916 experienced recurrence, second primary tumor, or death. The findings were analyzed exhaustively (1).Keywords
This publication has 6 references indexed in Scilit:
- EUROSCAN, a Randomized Trial of Vitamin A and N-Acetylcysteine in Patients With Head and Neck Cancer or Lung CancerJNCI: Journal of the National Cancer Institute, 2000
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- CHEMOPREVENTION OF LUNG CANCER: The Rise and Demise of Beta-CaroteneAnnual Review of Public Health, 1998
- Risk Factors for Lung Cancer and for Intervention Effects in CARET, the Beta-Carotene and Retinol Efficacy TrialJNCI: Journal of the National Cancer Institute, 1996
- Improvement in Bronchial Squamous Metaplasia in Smokers Treated With Folate and Vitamin B12JAMA, 1988
- Experimental cancer of the lung.Inhibition by vitamin A of the induction of tracheobronchial squamous metaplasia and squamous cell tumorsCancer, 1967